A complete response letter (CRL) from the FDA delays a product's entry to the market by an average of 14 months. Companies that receive the letters take an average of seven months just to respond to them. Imagine how much you could save if you could anticipate the FDA's concerns and address them before the agency issues the complete response letter? Now you can.
Novartis AG wants patients to stop taking one of its best-selling drugs. The Swiss company revolutionized leukemia treatment with Gleevec, a drug that turned a deadly blood cancer into a chronic disease more than a decade ago. Businessweek